Ibiglustat (L-Malic acid)

1629063-78-0

C24H30FN3O7S

DMSO : >= 102 mg/mL (194.82 mM)

Others

Ibiglustat L-Malic acid (Venglustat L-Malic acid), a potential therapy for PD Parkinson�s disease, SRT in Fabry�s and Gaucher�s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier^[1][2][3]. IC50 & Target: Glucosylceramide synthase^[1]. In Vitro: Ibiglustat (SAR402671) (1 uM, 15 days) treated FD cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes^[4].